Filing Analysis
ChronoScale Holdings Corp announced an extension of its strategic partnership with Microsoft Corporation. The partnership, which supports a 50-megawatt AI compute deployment, has been extended from a two-year term to a three-year term.
🚩 Red Flags
- Forward-looking statement warnings regarding cash flow and access to capital (noted in cautionary language).
📋 Key Facts
- Strategic partnership with Microsoft Corporation for a 50-megawatt (MW) AI compute deployment.
- The term of the partnership has been extended from two years to three years.
- The announcement was made via press release on August 27, 2026.
ChronoScale Holdings Corp announced a new employment agreement for its Chief Financial Officer, Jerome Wong, effective August 16, 2026. The agreement includes a salary increase, a performance bonus target, and a grant of 300,000 restricted stock units (RSUs).
🚩 Red Flags
- The 'true-up' provision suggests a retroactive salary adjustment, which can sometimes indicate previous compensation discrepancies or a sudden need to retain key personnel.
📋 Key Facts
- Jerome Wong entered into an 'Offer of Continued Employment' as CFO on August 16, 2026.
- Annual base salary set at $400,000.
- Target annual performance bonus of 60% of base salary.
- Grant of 300,000 restricted stock units (RSUs) subject to time-based vesting.
- Includes a 'true-up' payment for salary differences dating back to May 5, 2026.
- Severance provisions include 9 months of salary/benefits for a Qualifying CIC Termination and 6 months for termination without Cause.
ChronoScale Corporation (formerly Ekso Bionics Holdings, Inc.) has filed an amendment to its 8-K to provide required financial statements and pro forma information following a completed business combination with Applied Digital Cloud Corporation. The filing includes audited combined financial statements for the acquired entity ('Cloud') and unaudited pro forma condensed combined balance sheets/income statements.
🚩 Red Flags
- Integration risk: The company explicitly notes difficulties and delays in integrating the combined business as a potential risk factor.
- Financial uncertainty: Mentions risks related to cash flow, access to capital, and the finalization of 2026 financial statements.
📋 Key Facts
- Business combination consummated on May 5, 2026, involving ChronoScale Corp (f/k/a Ekso Bionics Holdings, Inc.) and Applied Digital Cloud Corporation.
- The company changed its name from Ekso Bionics Holdings, Inc. to ChronoScale Corporation.
- Filing includes audited combined financial statements for 'Cloud' for fiscal years ended May 31, 2025, and May 31, 2024 (Exhibit 99.2).
- Includes unaudited pro forma condensed combined balance sheet as of February 28, 2026, and statement of operations for nine months ended February 28, 2026.
- The filing is an 'Amendment No. 2' to satisfy previous disclosure requirements regarding the acquisition.
ChronoScale Corporation expanded its Board of Directors to eight members with the appointment of Andrew Cordell Schaap. Mr. Schaap will also serve on the Audit and Related Party Transactions Committees, replacing Douglas Miller in the latter role.
🚩 Red Flags
- Potential related-party transaction: The Company's subsidiary is a party to a data center lease with a company where the new director (Mr. Schaap) is the CEO.
📋 Key Facts
- Board size increased from seven to eight members effective June 29, 2026.
- Andrew Cordell Schaap appointed to Board, Audit Committee, and Related Party Transactions Committee.
- Douglas Miller replaced on the Related Party Transactions Committee but remains on the Board.
- Mr. Schaap granted a Restricted Stock Award (RSA) of 200,000 shares vesting in two equal annual installments.
- A subsidiary has an existing data center lease with a company where Mr. Schaap serves as CEO.
ChronoScale Corporation entered into a $100 million unsecured Demand Grid Promissory Note with Applied Digital Corporation, which holds approximately 96% of ChronoScale's common stock. The agreement is a related-party transaction involving shared board members and overlapping corporate control.
🚩 Red Flags
- Significant related-party transaction: The lender owns 96% of the borrower.
- Control overlap: Multiple directors (Cummins, Benson, Miller, Nottenburg) serve on both boards.
- Demand Note structure: 'Demand' notes can be called by the lender at any time, creating significant liquidity risk for the company.
📋 Key Facts
- Entered into an unsecured Demand Grid Promissory Note on June 26, 2026.
- Maximum principal amount: $100,000,000 (subject to credit support adjustments).
- Lender (Applied Digital Corporation) and its affiliates hold ~96% of the Company's common stock.
- Interest rate is equal to the short-term Applicable Federal Rate (AFR), compounded semiannually.
- The Note is not convertible into common stock.
- Wes Cummins serves as CEO/Chairman for both the Lender and sits on the Company Board.
ChronoScale Corporation has committed to a plan to divest its wholly owned subsidiary, Ekso Bionics, Inc., to pivot its business focus exclusively toward its cloud operations. The company expects to complete this divestiture during the first fiscal quarter but anticipates incurring material exit charges.
🚩 Red Flags
- Material charges expected from the divestiture without a current estimate of the total amount.
- Significant pivot in business strategy (divesting a wholly owned subsidiary) often indicates failure of the previous business segment or urgent liquidity needs.
📋 Key Facts
- Board commitment to divest Ekso Bionics, Inc. occurred on May 29, 2026.
- The company intends to focus operations solely on its cloud business.
- Divestiture is expected to be completed during the first fiscal quarter.
- Anticipated costs include severance, lease termination payments, and transaction-related expenses.
- The company is currently unable to provide a good-faith estimate of the total costs associated with the exit.
ChronoScale Corporation filed an 8-K/A to amend the settlement terms of Phantom Performance-Based Stock Units (PSUs) for three executives. The company shifted the settlement from cash-only to a combination of common stock and cash following a 'Change in Control' event and the achievement of stock price goals.
🚩 Red Flags
- Significant cash payout of $1,000,000 to a single executive (Scott G. Davis) which may impact liquidity for a micro-cap company.
- Amendment of original award terms (changing cash-only to equity) suggests a desire to preserve cash or align executive interests post-control change.
📋 Key Facts
- Phantom PSUs were originally granted on November 5, 2025, to Scott G. Davis (185k), Jerome Wong (40k), and Jason Jones (32k).
- A 'Change in Control' was triggered by a Contribution and Exchange Agreement dated February 15, 2026, which closed on May 5, 2026.
- Settlement terms were amended on May 14, 2026, to move away from cash-only payments.
- Scott G. Davis will receive 109,357 shares of Common Stock and $1,000,000 in cash.
- Jerome Wong and Jason Jones will receive 40,000 and 32,000 shares of Common Stock, respectively.
- Settlements must be completed by March 15, 2027.
Ekso Bionics Holdings, Inc. has completed a business combination with Applied Digital Corporation's subsidiary, Cloud, resulting in a name change to ChronoScale Corporation and a change in ticker symbol to 'CHRN'. The transaction involved a PIPE investment of $15.75 million and a massive issuance of shares, effectively transferring control of the company to Applied Digital.
🚩 Red Flags
- Extreme dilution of legacy shareholders (reduced to ~3% ownership)
- Loss of corporate control to a single entity (Applied Digital)
- Significant restrictive covenants in the Investor Rights Agreement requiring Applied Parent's consent for fundamental changes, dividends, and asset sales
📋 Key Facts
- Closing Date: May 5, 2026
- Company name changed from Ekso Bionics Holdings, Inc. to ChronoScale Corporation
- Ticker symbol changed to 'CHRN' on Nasdaq Capital Market
- Applied Parent invested approximately $15.75 million via a PIPE investment (1,311,407 shares at $12.01/share)
- Applied Parent/Contributor now hold approximately 97% of outstanding Common Stock
- Legacy shareholders now hold approximately 3% of outstanding Common Stock
- Total shares outstanding post-closing: 143,093,381
- Fiscal year end changed to May 31st
- Applied Parent has the right to designate 4 of 7 board directors
Ekso Bionics is finalizing a transformative business combination with subsidiaries of Applied Digital Corporation, resulting in a name change to ChronoScale Corporation and a ticker change to CHRN. The transaction includes a $15.75 million PIPE investment from Applied Digital at $12.01 per share.
🚩 Red Flags
- Significant dilution expected from the issuance of 'Exchanged Shares' and the 1.3M share PIPE investment.
- The company is undergoing a fundamental pivot in business identity (from Bionics to 'ChronoScale' / Cloud infrastructure).
- Complex execution timeline with minute-by-minute effective steps suggests high execution risk.
📋 Key Facts
- Business combination with APLD Intermediate HoldCo LLC and Applied Digital Cloud Corporation to close May 5, 2026.
- Company name will change to ChronoScale Corporation and ticker will change from EKSO to CHRN.
- Applied Digital Corporation (Applied Parent) is purchasing 1,311,407 shares at $12.01 per share for $15.75 million in gross proceeds.
- Lake Street Capital Markets to receive a 5% cash fee ($0.75 million) as placement agent.
- The closing involves a multi-step process including the filing of Second Amended and Restated Articles of Incorporation.
- The CUSIP number for the Common Stock will change to 170924 104.
Ekso Bionics Holdings, Inc. has entered into a definitive Contribution and Exchange Agreement to undergo a business combination with Cloud (a subsidiary of Applied Digital Corporation). The transaction will result in the company changing its name to ChronoScale Corporation and being controlled by APLD investors.
🚩 Red Flags
- Extreme dilution: The issuance of over 138 million new shares will significantly dilute existing Ekso shareholders.
- Severe liquidity crisis: Estimated cash as of Dec 31, 2025, is only $1.2 million, which is far below the $15 million closing condition required for the deal.
- Control shift: The existing shareholders will be diluted to approximately 3% ownership (APLD to own ~97%).
- Revenue decline: Q4 2025 revenue ($3.0M-$3.1M) is significantly down from Q4 2024 ($5.1M).
📋 Key Facts
- Business combination with Cloud (subsidiary of Applied Digital Corporation/APLD) expected to close in Q2 2026.
- Upon closing, Contributor is expected to own approximately 97% of the combined company's outstanding equity.
- Ekso will change its name to ChronoScale Corporation following the transaction.
- The deal involves the issuance of 138,216,820 newly issued shares of Ekso common stock in exchange for 1,200 shares of Cloud.
- A PIPE investment is required as a condition to closing; current cash on hand is estimated at only $1.2 million as of Dec 31, 2025.
- The Investor Rights Agreement grants APLD-related investors the right to designate four of seven directors, including the Chairman.
Ekso Bionics Holdings, Inc. completed a private placement of Series B Convertible Preferred Stock and warrants to raise approximately $5.3 million in net proceeds for working capital. The offering includes significant conversion rights and protective provisions that grant preferred holders substantial control over certain corporate actions.
🚩 Red Flags
- Significant potential dilution: The conversion of preferred stock into common stock represents a large number of new shares (711,922 shares).
- Protective provisions: Preferred holders have veto power over key corporate actions, including changes to the articles of incorporation or issuance of senior securities.
- Redemption risk: Holders have the option to redeem shares at stated value after one year, which could create sudden cash flow pressure.
- Warrant overhang: The issuance of warrants creates additional potential dilution for existing shareholders.
📋 Key Facts
- Raised approximately $5.3 million in net proceeds via a private placement of Series B Convertible Preferred Stock.
- Series B Preferred Stock has a stated value of $1,000 per share and is convertible into common stock at $8.22 per share.
- The offering includes warrants to purchase up to 355,960 shares of Common Stock at an exercise price of $8.22 per share.
- Series B Preferred Stock carries protective provisions requiring a majority vote from holders for actions like altering stock rights or issuing senior securities.
- Shares are redeemable by the holder at the Stated Value starting one year after closing (January 22, 2027).
- Registration statement for resale of shares is required to be filed by June 1, 2026.
Ekso Bionics Holdings has entered into a non-binding term sheet for a business combination with Applied Digital Corporation's cloud computing unit, 'Applied Digital Cloud.' The transaction would create a new entity called ChronoScale Corporation focused on AI workloads, resulting in significant dilution for existing Ekso shareholders.
🚩 Red Flags
- Extreme dilution: Existing Ekso shareholders are expected to be diluted down to approximately 3% ownership in the combined entity.
- Pivot in core business: The transaction represents a fundamental shift from medical robotics to AI-focused cloud computing infrastructure.
- Uncertainty of consummation: The term sheet is non-binding and subject to customary closing conditions.
📋 Key Facts
- Entered into an exclusive, non-binding term sheet for a business combination with Applied Digital Cloud.
- The combined company will be named ChronoScale Corporation.
- Post-transaction ownership: Applied would own approximately 97% of the combined company; existing Ekso stockholders expected to hold ~3%.
- Ekso plans to continue exploring strategic transactions for the possible sale of all or substantially all of its current business.
- Transaction is subject to due diligence, regulatory/stockholder approvals, and definitive agreements.
Ekso Bionics has granted significant equity awards and entered into new severance agreements with three key executives (Scott Davis, Jerome Wong, and Jason Jones). The new agreements include enhanced severance protections triggered by a Change in Control.
🚩 Red Flags
- Significant equity grants to executives that are already fully vested (RSUs).
- Severance packages specifically structured around a potential Change in Control, which may incentivize management to seek a sale.
- Phantom PSUs require a stock price of $7.50 for vesting, creating a potential misalignment if the current market price is significantly lower.
📋 Key Facts
- Granted RSUs to Scott Davis (80,000), Jerome Wong (19,500), and Jason Jones (15,000) which are fully vested as of the grant date.
- Granted Phantom PSUs to executives with a 5-year vesting period contingent on: (i) a Change in Control and (ii) achieving a stock price of at least $7.50.
- Entered into new Change in Control and Severance Agreements for all three executives effective November 5, 2025.
- Severance terms include lump sum salary payments (9-18 months) and medical coverage if terminated without cause or via resignation for 'Good Reason' during a Change in Control period.
Ekso Bionics Holdings, Inc. announced a registered direct offering of 769,490 shares at $4.81 per share to institutional investors. The company intends to use the approximately $3.2 million in net proceeds for general corporate purposes, including R&D and working capital.
🚩 Red Flags
- Dilutive offering for existing shareholders.
- Use of proceeds specifically mentions 'meeting working capital needs,' which can indicate liquidity constraints in micro-cap companies.
📋 Key Facts
- Offering size: 769,490 shares of common stock.
- Offering price: $4.81 per share.
- Expected net proceeds: Approximately $3.2 million (after fees/expenses).
- Placement Agent: Lake Street Capital Markets, LLC.
- Placement Agent Fee: 6% cash fee plus a warrant to purchase up to 15,389 shares at $4.81 per share.
- Purpose of funds: R&D, SG&A, strategic initiatives, and working capital needs.
Ekso Bionics Holdings, Inc. filed an 8-K to announce its financial results for the three and nine months ended September 30, 2025. The filing serves as a formal notification that earnings data is being released via press release.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2025.
- Filing date: October 28, 2025.
- The financial results were announced via a press release attached as Exhibit 99.1.
Ekso Bionics entered into a $2.0 million secured promissory note with B. Riley Commercial Capital, LLC to fund working capital. The loan is tied to an upcoming 'Qualified Financing' and carries high-cost terms including a 10% exit fee.
🚩 Red Flags
- High-cost financing structure including a 10% exit fee ($200,000).
- Loan maturity is contingent upon a 'Qualified Financing' of $2.4 million, indicating potential liquidity pressure.
- Debt is secured by substantially all personal property of the Company and its subsidiary.
- The loan serves as bridge financing to an uncertain equity event.
📋 Key Facts
- Entered into a Secured Promissory Note on September 12, 2025, with B. Riley Commercial Capital, LLC.
- Principal amount: Up to $2.0 million for working capital and general corporate purposes.
- Maturity Date: Either upon receipt of $2.4 million from new equity investors (Qualified Financing) or September 14, 2026.
- Interest Rate: 10.0% per annum, with a default rate of 15.0% (5.0% above the base rate).
- Exit Fee: 10% of original principal ($200,000) payable at maturity.
- Security: Secured by substantially all personal property of the Company and its subsidiary.
- Conversion Right: Lender may convert debt into equity at the price paid by lead investors in a Qualified Financing.
Ekso Bionics Holdings, Inc. has filed an 8-K to announce its financial results for the three and six months ended June 30, 2025.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2025.
- Filing date: July 28, 2025.
- The filing includes a press release (Exhibit 99.1) detailing the company's financial condition and results of operations.
Ekso Bionics Holdings, Inc. has rescheduled the effective date of its stockholder-approved reverse stock split to June 2, 2025. The split aims to increase the share price to regain compliance with Nasdaq's minimum bid price requirement.
🚩 Red Flags
- Reverse stock split is being used as a remedial measure for Nasdaq non-compliance.
- Company received notice of failure to meet minimum bid price requirements on December 12, 2024.
- Significant reduction in the number of outstanding shares (expected ~2.4 million total).
📋 Key Facts
- Reverse stock split ratio is set at 1-for-15.
- The effective date has been moved from May 27, 2025, to June 2, 2025, at 12:01 a.m. PT.
- Post-split, the company expects to have approximately 2.4 million shares of common stock outstanding.
- The split will affect all issued and outstanding common stock, restricted stock units, options, and warrants.
- Fractional shares resulting from the split will be rounded up to the next whole share.
Ekso Bionics Holdings, Inc. held its 2025 Annual Meeting where stockholders approved a reverse stock split to maintain Nasdaq listing requirements. The Board has set the ratio at 1-for-15, effective May 27, 2025.
🚩 Red Flags
- Reverse stock split (Red flag escalator)
- Delisting risk/Nasdaq non-compliance regarding minimum bid price
- Significant reduction in total outstanding shares (from ~36M to ~2.4M)
📋 Key Facts
- Stockholders approved a reverse stock split with a range of 1-for-5 to 1-for-15; the Board selected a 1-for-15 ratio.
- The Reverse Stock Split is scheduled to become effective at 12:01 a.m. PT on May 27, 2025.
- Post-split, the company expects to have approximately 2.4 million shares of common stock outstanding.
- The split aims to address a failure to meet Nasdaq's minimum bid price requirement (notified Dec 12, 2024).
- Five directors were elected to serve until the 2026 annual meeting.
- Stockholders approved an increase in shares authorized for the 2014 Equity Incentive Plan.
Ekso Bionics Holdings, Inc. filed an 8-K to announce its financial results for the three months ended March 31, 2025. The filing serves as a formal notification of the release of quarterly earnings via press release.
📋 Key Facts
- Reporting period: Three months ended March 31, 2025.
- Filing date: May 5, 2025.
- The filing includes Exhibit 99.1 containing the full text of the press release regarding financial results.
Ekso Bionics entered into a warrant inducement agreement with an existing investor to encourage the exercise of Series A and B warrants at a reduced price. In exchange, the company is issuing new warrants for 10.5 million shares, subject to stockholder approval.
🚩 Red Flags
- Significant potential dilution: The issuance of up to 10.5 million new warrants and the exercise of 9.8 million existing shares represents a massive increase in share count.
- Low-priced warrant exercise ($0.4239) suggests significant downward pressure on stock price or distress in capital structure.
- Requirement for stockholder approval indicates the transaction is large enough to trigger Nasdaq regulatory scrutiny regarding dilution.
📋 Key Facts
- Investor agreed to exercise all Existing Investor Warrants (9.8M shares) at a reduced price of $0.4239 per share.
- Company to issue a new Inducement Warrant for up to 10,500,000 shares of Common Stock.
- Inducement Warrant exercise price is set at $0.4239 per share.
- The company must seek stockholder approval for the Inducement Warrant by July 15, 2025.
- Company is prohibited from issuing common stock or entering Variable Rate Transactions until May 31, 2025 (with some exceptions).
- Beneficial ownership limitations are set at 4.99% (can be increased to 9.99% with notice).
Ekso Bionics Holdings, Inc. has filed an 8-K to announce its financial results for the three and twelve months ended December 31, 2024.
📋 Key Facts
- Reporting period: Three and twelve months ended December 31, 2024.
- Filing date: March 3, 2025.
- The filing includes a press release (Exhibit 99.1) containing the results of operations and financial condition.
Ekso Bionics Holdings, Inc. released preliminary financial results for the fourth quarter of 2024, reporting record revenue despite a decrease in cash position. The company noted that these figures are unaudited and subject to adjustment during the finalization of year-end financial statements.
🚩 Red Flags
- Cash position declined by approximately $2.1 million year-over-year (from $8.6M to $6.5M).
- Ongoing negative cash flow from operations ($1.5M used in Q4 2024).
📋 Key Facts
- Estimated Q4 2024 total revenue: $5.0 million - $5.1 million (a record for the company).
- Q4 2023 total revenue was $4.8 million.
- Estimated cash as of Dec 31, 2024: $6.5 million (down from $8.6 million on Dec 31, 2023).
- Estimated net cash used in operations for Q4 2024: $1.5 million.
- Preliminary results are unaudited and subject to potential material adjustments during the closing process.
Ekso Bionics Holdings, Inc. received a notice from Nasdaq indicating the company is in violation of the minimum bid price requirement after its stock traded below $1.00 for 31 consecutive business days. The company has been granted an initial 180-day compliance period ending June 10, 2025.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5550(a)(2))
- Potential requirement for a reverse stock split to maintain listing
- Prolonged period of sub-$1.00 trading (31+ consecutive business days)
📋 Key Facts
- Received written notice from Nasdaq on December 12, 2024, regarding a violation of Nasdaq Listing Rule 5550(a)(2).
- The company's common stock has been below the $1.00 minimum bid price for 31 consecutive business days.
- Initial compliance period expires on June 10, 2025.
- To regain compliance, the closing bid price must be $1.00 or more for at least ten consecutive business days before the deadline.
- The company may need to implement a reverse stock split to qualify for an additional 180-day extension if it fails the initial period.
Ekso Bionics Holdings, Inc. filed an 8-K to announce its financial results for the three and nine months ended September 30, 2024.
📋 Key Facts
- Reporting period: Three and nine months ended September 30, 2024.
- Filing date: October 28, 2024.
- The filing includes a press release as Exhibit 99.1 containing the full financial results.
Ekso Bionics Holdings, Inc. completed a public offering of common stock and various warrants on September 3, 2024, raising approximately $5.1 million in net proceeds. The offering included significant warrant components that will result in substantial future dilution.
🚩 Red Flags
- Significant Dilution Risk: The issuance of 6 million Series A Warrants, 6 million Series B Warrants, and 2.9 million Pre-Funded Warrants represents a massive potential increase in share count.
- Low Exercise Price: Pre-funded warrants are exercisable at $0.001 per share, which is highly dilutive to existing shareholders.
- Capital Raise Context: The relatively small net proceeds ($5.1M) compared to the volume of warrants issued suggests a high cost of capital and potential liquidity pressure.
📋 Key Facts
- Public Offering: 3,100,000 units at $1.00 per unit (each unit contains 1 share of common stock, one Series A Warrant, and one Series B Warrant).
- Pre-funded Units: 2,900,000 pre-funded units at $0.9990 per unit (each contains a Pre-Funded Warrant, one Series A Warrant, and one Series B Warrant).
- Net proceeds to the Company: Approximately $5.1 million.
- Series A Warrants: 6,000,000 warrants exercisable at $1.00 per share (expires in 5 years).
- Series B Warrants: 6,000,000 warrants exercisable at $1.00 per share (expires in 1 year).
- Pre-Funded Warrants: 2,900,000 warrants exercisable at $0.001 per share.
- Lock-up period: 90 days for the company and executive officers/directors.
Ekso Bionics Holdings, Inc. filed an 8-K to announce its financial results for the three and six months ended June 30, 2024.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2024.
- Filing date: July 29, 2024.
- The filing serves to furnish financial results via a press release (Exhibit 99.1).
This is an amendment to a previous 8-K filing regarding the results of the 2024 Annual Meeting. The Company's Board has decided to hold advisory votes on executive compensation (Say-on-Pay) on an annual basis, aligning with stockholder voting trends.
📋 Key Facts
- The filing is an Amendment No. 1 to an Initial 8-K originally filed on June 10, 2024.
- On July 25, 2024, the Board determined that future advisory votes on executive compensation will be held annually.
- The decision aligns with the Board's recommendation in the proxy statement and reflects voting results from the Annual Meeting held on June 6, 2024.
Ekso Bionics Holdings, Inc. held its 2024 Annual Meeting of Stockholders on June 6, 2024. The company successfully passed all proposals, including the election of five directors and the ratification of their independent auditor.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Quorum was established with 11,425,241 shares present out of 18,099,260 total outstanding shares (approx. 63% participation).
- Five directors were elected: Scott G. Davis, Mary Ann Cloyd, Corinna Lathan, Ph.D., Charles Li, Ph.D., and Deborah Lafer Scher.
- Stockholders approved the extension of the Amended and Restated 2014 Equity Incentive Plan until April 15, 2034.
- The equity plan increase authorized an additional 1,000,000 shares for issuance under said plan.
- WithumSmith+Brown, PC was ratified as the independent auditor for the fiscal year ending December 31, 2024.
Ekso Bionics Holdings, Inc. filed an 8-K to announce its financial results for the three months ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings and includes a press release as Exhibit 99.1.
📋 Key Facts
- Reporting period: Three months ended March 31, 2024.
- Filing date: April 29, 2024.
- The filing contains results of operations and financial condition under Item 2.02.
Ekso Bionics Holdings, Inc. filed an 8-K to announce its financial results for the three and twelve months ended December 31, 2023.
📋 Key Facts
- Reporting period: Three and twelve months ended December 31, 2023.
- Filing date: March 4, 2024.
- The filing includes a press release (Exhibit 99.1) detailing the company's financial condition and operations.
Ekso Bionics Holdings, Inc. entered into a securities purchase agreement to conduct a registered direct offering of 2,967,742 shares at $1.55 per share. The net proceeds are expected to be approximately $4.0 million to fund general corporate purposes and working capital.
🚩 Red Flags
- Significant dilution: The offering of nearly 3 million shares at a low price point ($1.55) suggests the company is seeking immediate liquidity.
- Anti-dilution trigger: The downward adjustment of existing warrants from $3.52 to $1.55 represents significant further dilution for existing shareholders.
- Small capital raise: A net proceed of $4 million is relatively small, suggesting a continuous need for cash to meet working capital needs.
📋 Key Facts
- Offered 2,967,742 shares of common stock via a registered direct offering.
- Offering price set at $1.55 per share.
- Expected net proceeds of approximately $4.0 million after fees and expenses.
- Placement agent (A.G.P./Alliance Global Partners) to receive a 7% fee plus expense reimbursements ($60,000 legal; $10,000 non-accountable).
- The offering triggered an anti-dilution adjustment for May 2019 warrants, reducing their exercise price from $3.52 to $1.55 per share.
- Closing occurred on or about January 16, 2024.
The filing is a formal submission of financial statements and exhibits as required under Item 9.01. It serves to provide the necessary consent from the independent auditor, WithumSmith+Brown, PC.
📋 Key Facts
- Filed on January 10, 2024
- Includes Exhibit 23.1: Consent of WithumSmith+Brown, PC (independent registered public accounting firm)
- Reported by Jerome Wong, Chief Financial Officer
Ekso Bionics Holdings, Inc. issued a press release announcing preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2023. While revenue shows growth, the company's cash position has significantly decreased.
🚩 Red Flags
- Significant reduction in cash reserves, dropping from $20.5 million to an estimated $8.6 million year-over-year.
- Preliminary results are unaudited and subject to material adjustments during the finalization of financial statements.
📋 Key Facts
- Q4 2023 estimated revenue: $4.7M - $4.9M (vs. $3.6M in Q4 2022).
- FY 2023 estimated revenue: $18.1M - $18.3M (vs. $12.9M in FY 2022).
- Estimated cash balance as of Dec 31, 2023: $8.6M (vs. $20.5M at Dec 31, 2022).
- Q4 2023 estimated cash use in operations: $1.7M (vs. $3.6M in Q4 2022).